Description of Business and Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands					1 Months Ended	12 Months Ended
	Aug. 18, 2022 USD ($) $ / shares shares	Jul. 06, 2021 USD ($) $ / shares shares	Aug. 25, 2020 USD ($) $ / shares shares	Aug. 20, 2020	Jul. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Aggregate proceeds from issuance of private placement						$ 174
Accumulated deficit						383,790	$ 228,982
Cash, cash equivalents and marketable securities						559,500
Reverse stock split, description							On August 20, 2020, the Board approved a 1-for-1.5949 reverse stock split of the Company’s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company’s outstanding series of preferred stock. All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
Reverse stock split				1.5949
Follow-on Offering
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Net proceeds from sale of common stock in public offering		$ 257,000
Stock Issued During Period, Shares, New Issues | shares		5,468,250
Common stock per share | $ / shares		$ 47.00
Initial Public Offering
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues | shares			9,987,520
Common stock per share | $ / shares			$ 20.00
Gross proceeds from issuance initial public offering			$ 199,800
Underwriters
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues | shares		713,250	1,302,720
Private Placement | Vertex Pharmaceuticals Incorporated
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Aggregate proceeds from issuance of private placement		$ 2,300	$ 13,500		$ 2,300
Stock Issued During Period, Shares, New Issues | shares		49,928	676,354
Common stock per share | $ / shares		$ 47.00	$ 20.00
Private Investment in Public Equity "PIPE"
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues | shares	2,769,228
Common stock per share | $ / shares	$ 26.00
Pre-funded warrant purchase price | $ / shares	25.9999
Pre-funded warrants per share | $ / shares	$ 0.0001
Offering expenses	$ 149,800
Minimum pre-funded warrants, exercise	4.99%
Increase or decrease pre-funded warrants, maximum	19.99%
Prior notice period, minimum	61 days
Pre-funded warrants, exercised						$ 0
Pre-funded warrants outstanding | shares	3,000,000					3,000,000